Literature DB >> 21466613

Mismatched human leukocyte antigen class II-restricted CD8⁺ cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation.

Tomoya Hirosawa1, Hiroki Torikai, Mayumi Yanagisawa, Michi Kamei, Nobuhiko Imahashi, Ayako Demachi-Okamura, Miyoko Tanimoto, Keiko Shiraishi, Mamoru Ito, Koichi Miyamura, Kiyosumi Shibata, Fumitaka Kikkawa, Yasuo Morishima, Toshitada Takahashi, Nobuhiko Emi, Kiyotaka Kuzushima, Yoshiki Akatsuka.   

Abstract

Partial human leukocyte antigen (HLA)-mismatched hematopoietic stem cell transplantation (HSCT) is often performed when an HLA-matched donor is not available. In these cases, CD8(+) or CD4(+) T cell responses are induced depending on the mismatched HLA class I or II allele(s). Herein, we report on an HLA-DRB1*08:03-restricted CD8(+) CTL clone, named CTL-1H8, isolated from a patient following an HLA-DR-mismatched HSCT from his brother. Lysis of a patient Epstein-Barr virus-transformed B cell line (B-LCL) by CTL-1H8 was inhibited after the addition of blocking antibodies against HLA-DR and CD8, whereas antibodies against pan-HLA class I or CD4 had no effect. The 1H8-CTL clone did not lyse the recipient dermal fibroblasts whose HLA-DRB1*08:03 expression was upregulated after 1 week cytokine treatment. Engraftment of HLA-DRB1*08:03-positive primary leukemic stem cells in non-obese diabetic/severe combined immunodeficient/γc-null (NOG) mice was completely inhibited by the in vitro preincubation of cells with CTL-1H8, suggesting that HLA-DRB1*08:03 is expressed on leukemic stem cells. Finally, analysis of the precursor frequency of CD8(+) CTL specific for recipient antigens in post-HSCT peripheral blood T cells revealed a significant fraction of the total donor CTL responses towards the individual mismatched HLA-DR antigen in two patients. These findings underscore unexpectedly significant CD8 T cell responses in the context of HLA class II.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466613     DOI: 10.1111/j.1349-7006.2011.01949.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  5 in total

Review 1.  Class II-Restricted CD8s: New Lessons Violate Old Paradigms.

Authors:  Stephen A Migueles; Mark Connors
Journal:  Immunity       Date:  2016-10-18       Impact factor: 31.745

2.  Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.

Authors:  Scott G Hansen; Jonah B Sacha; Colette M Hughes; Julia C Ford; Benjamin J Burwitz; Isabel Scholz; Roxanne M Gilbride; Matthew S Lewis; Awbrey N Gilliam; Abigail B Ventura; Daniel Malouli; Guangwu Xu; Rebecca Richards; Nathan Whizin; Jason S Reed; Katherine B Hammond; Miranda Fischer; John M Turner; Alfred W Legasse; Michael K Axthelm; Paul T Edlefsen; Jay A Nelson; Jeffrey D Lifson; Klaus Früh; Louis J Picker
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

3.  Antiviral CD8+ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion.

Authors:  Srinika Ranasinghe; Pedro A Lamothe; Damien Z Soghoian; Samuel W Kazer; Michael B Cole; Alex K Shalek; Nir Yosef; R Brad Jones; Faith Donaghey; Chioma Nwonu; Priya Jani; Gina M Clayton; Frances Crawford; Janice White; Alana Montoya; Karen Power; Todd M Allen; Hendrik Streeck; Daniel E Kaufmann; Louis J Picker; John W Kappler; Bruce D Walker
Journal:  Immunity       Date:  2016-10-18       Impact factor: 31.745

4.  HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.

Authors:  Tinashe E Nyanhete; Alyse L Frisbee; Todd Bradley; William J Faison; Elizabeth Robins; Tamika Payne; Stephanie A Freel; Sheetal Sawant; Kent J Weinhold; Kevin Wiehe; Barton F Haynes; Guido Ferrari; Qi-Jing Li; M Anthony Moody; Georgia D Tomaras
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

5.  A novel and efficient method to induce allospecific CD8+ memory T lymphocytes.

Authors:  Lei Yang; Qingyun Huang; Jianping Fu; Zhimin Lin; Qiqi Mao; Lili Zhao; Xingxin Gao; Songlin Chen; Guangzong Hua; Sheng Li
Journal:  J Clin Lab Anal       Date:  2021-08-31       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.